{"product_id":"eirgenix-swot-analysis","title":"EirGenix SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEirGenix's SWOT analysis reveals a strong foundation in biopharmaceutical manufacturing, highlighting its advanced capabilities and established partnerships as key strengths. However, understanding the full scope of its market challenges and potential growth avenues requires a deeper dive.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind EirGenix's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Services and Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEirGenix excels by providing a full spectrum of services for biologics, from initial cell line development all the way through to commercial-scale cGMP manufacturing. This integrated approach means clients have one trusted partner managing the entire journey for both biosimilars and innovative biologic drugs.\u003c\/p\u003e\n\u003cp\u003eThis end-to-end capability significantly simplifies the complex development pathway for their clients, offering a streamlined, single-source solution. EirGenix's proven track record includes successfully completing over 50 challenging biologics projects, encompassing advanced modalities like antibody-drug conjugates (ADCs) and multispecific antibodies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Regulatory Compliance and Global Certifications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEirGenix stands out with an exceptional regulatory compliance record, being the sole biologics manufacturing facility in Taiwan holding certifications from key global health authorities. This includes approvals from the U.S. Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), the European Medicines Agency (EMA), Australia's Therapeutic Goods Administration (TGA), and Taiwan's own Food and Drug Administration (TFDA).\u003c\/p\u003e\n\u003cp\u003eThis extensive multi-agency certification is a significant strength, underscoring EirGenix's commitment to stringent quality standards. It directly translates to reduced regulatory complexities for their clients, paving a smoother path for product approval and market entry across major international territories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Manufacturing Capacity and Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEirGenix boasts a robust manufacturing infrastructure, featuring 12 mammalian cell production lines, each with a 2,000-liter capacity at its Zhubei facility. This setup allows for an impressive annual output of up to 1,000 kg of antibody.\u003c\/p\u003e\n\u003cp\u003eThe company is strategically investing in growth, actively expanding its manufacturing capabilities. Plans include the installation of additional bioreactors and the establishment of new production lines to cater to the escalating demand for large-scale commercial manufacturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships and Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEirGenix excels at building strategic partnerships, a key strength for expanding its reach. A prime example is their agreement with Japan's Mitsubishi Gas Chemical and Taiwan's GlycoNex, which facilitates the pre-commercial production of the biosimilar drug SPD8. This type of collaboration is crucial for gaining traction in new markets.\u003c\/p\u003e\n\u003cp\u003eThese alliances directly boost EirGenix's market penetration. Notably, recent contracts in Japan now represent over 45% of their total agreements, underscoring the success of their partnership strategy in that region. Furthermore, the U.S. Biologics Security Act provides a favorable environment for EirGenix's growth in the American market, supported by these strategic collaborations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eTripartite agreement with Mitsubishi Gas Chemical and GlycoNex for SPD8 production.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eOver 45% of recent agreements are with Japanese partners.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLeveraging the U.S. Biologics Security Act for market entry.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDual Business Model: CDMO and Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEirGenix uniquely leverages a dual business model, acting as both a Contract Development and Manufacturing Organization (CDMO) for other companies and a developer of its own innovative biologics. This hybrid approach creates a robust revenue stream from CDMO services, ensuring financial stability, while simultaneously pursuing high-growth opportunities through its proprietary product pipeline.  For instance, their CDMO segment reported significant revenue growth in the first half of 2024, contributing to overall company expansion.\u003c\/p\u003e\n\u003cp\u003eThis diversification strategy is particularly advantageous. The CDMO operations provide consistent cash flow, which can then be reinvested into the company's internal product development efforts. This allows EirGenix to de-risk its innovation pipeline and maintain operational momentum. Their breast cancer biosimilar, EG12014, exemplifies this, having received positive regulatory opinions, signaling strong potential for future commercial success.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eDual Revenue Streams:\u003c\/strong\u003e CDMO services provide stable income, while proprietary products offer high-value upside.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRisk Mitigation:\u003c\/strong\u003e CDMO cash flow supports the development of EirGenix's own drug pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Advancement:\u003c\/strong\u003e Projects like EG12014, a breast cancer biosimilar, demonstrate the potential of their internal development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Resilience:\u003c\/strong\u003e The combined model enhances EirGenix's ability to navigate market fluctuations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Biologics: End-to-End Development, Proven Expertise, Robust Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEirGenix's integrated, end-to-end services for biologics development and manufacturing are a significant strength, simplifying the process for clients. Their proven track record, including over 50 complex biologics projects, highlights their capability across advanced modalities. Furthermore, their robust manufacturing infrastructure, with 12 production lines capable of 2,000-liter batches, allows for substantial annual output.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of EirGenix’s internal and external business factors, highlighting its competitive position and market challenges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable roadmap by highlighting EirGenix's competitive advantages and areas for improvement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on External Funding and Negative Free Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEirGenix faces a significant weakness in its persistent negative free cash flow, which worsened from -200 million TWD in 2021 to -1.24 billion TWD by 2024. This cash burn is a direct result of substantial capital expenditures required for ongoing facility expansion and crucial drug development programs.  The company's continued reliance on external funding to bridge this gap presents a considerable risk, potentially impacting its financial flexibility and growth trajectory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Gross Profit Ratio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEirGenix's gross profit ratio has experienced a significant downturn, falling from 64% in 2021 to just 22% in 2024. This sharp decline indicates that the company is earning less from its core operations after accounting for the cost of goods sold.\u003c\/p\u003e\n\u003cp\u003eThis contraction in profitability is likely due to a combination of factors, including falling revenues and rising costs. These pressures are not unique to EirGenix, as the broader Taiwanese biopharma industry has grappled with global supply chain disruptions and the inherent complexities and costs associated with research and development cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition in the CDMO Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe biologics contract development and manufacturing organization (CDMO) sector is incredibly crowded. Major global players such as Lonza, Thermo Fisher Scientific, and Catalent often have the advantage of scale and existing relationships, making it a challenge for smaller or mid-sized companies like EirGenix to secure significant new business. This intense rivalry can put pressure on pricing and profit margins.\u003c\/p\u003e\n\u003cp\u003eFor companies like EirGenix, a key weakness stems from the potential for capacity underutilization. When clients complete their current projects and don't immediately initiate new ones, CDMOs can find themselves with idle manufacturing space. This was a concern across the industry in 2024, as some biopharma companies adjusted their R\u0026amp;D pipelines, leading to a more cautious approach to outsourcing new development programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChallenges in Cell and Gene Therapy (CGT) Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eWhile EirGenix provides extensive biologics manufacturing, the cell and gene therapy (CGT) sector presents distinct hurdles. Industry-wide issues like the absence of standardized processes, complex quality control measures, and a scarcity of skilled personnel are significant deterrents. These factors contribute to a cautious market outlook for CGT contract development and manufacturing organizations (CDMOs).\u003c\/p\u003e\n\u003cp\u003eThe CGT market is anticipated to experience continued subdued demand through 2025. This slowdown is largely attributed to existing overcapacity within the sector, impacting the growth trajectory for specialized CDMOs. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eLack of Standardization:\u003c\/strong\u003e Inconsistent manufacturing protocols across CGT products hinder scalability and efficiency.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eQuality Assurance Complexities:\u003c\/strong\u003e Ensuring the safety and efficacy of living cell and gene products presents unique QA challenges.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkforce Shortages:\u003c\/strong\u003e A critical deficit in trained scientists and technicians specializing in CGT manufacturing limits operational capacity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Overcapacity:\u003c\/strong\u003e A surplus of manufacturing capacity in the CGT space is projected to dampen demand for CDMO services into 2025, with some reports indicating a potential 20% excess capacity in certain segments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Geopolitical and Regulatory Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEirGenix, like other players in the biopharmaceutical sector, faces significant vulnerabilities stemming from geopolitical shifts and evolving regulatory landscapes. The global nature of the industry means that international disputes or trade policy changes can disrupt supply chains and market access. For instance, the proposed US BIOSECURE Act, aimed at strengthening domestic biomanufacturing capabilities, could potentially reshape global partnerships and sourcing strategies for companies with international operations, creating an environment of uncertainty.\u003c\/p\u003e\n\u003cp\u003eThese external pressures can translate into tangible financial risks. Fluctuations in currency exchange rates due to geopolitical instability, or increased compliance costs associated with new or changing regulations in key markets, can directly impact profitability. Companies must navigate these complexities, which often require substantial investment in legal counsel, lobbying efforts, and supply chain diversification to mitigate potential disruptions and ensure continued market access.\u003c\/p\u003e\n\u003cp\u003eThe biopharmaceutical industry's reliance on global research collaboration and distribution networks makes it particularly sensitive to these factors. A company like EirGenix, which may engage in international partnerships for drug development or manufacturing, could see its operations directly affected by trade sanctions or national security concerns that restrict cross-border data or material flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeopolitical Instability:\u003c\/strong\u003e Disruptions to global trade routes and international collaborations can impact EirGenix's supply chain and market reach.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Uncertainty:\u003c\/strong\u003e Evolving legislation, such as the US BIOSECURE Act, may necessitate costly adjustments to manufacturing processes or market strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompliance Costs:\u003c\/strong\u003e Adhering to diverse and changing international regulatory standards requires significant financial and operational resources.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash Burn Escalates: Investments Drive Negative Free Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEirGenix's financial health remains a key weakness, evidenced by its escalating negative free cash flow, which ballooned from -200 million TWD in 2021 to -1.24 billion TWD by 2024. This significant cash burn is driven by substantial investments in facility expansions and ongoing drug development, necessitating continuous external funding and potentially limiting financial maneuverability.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eEirGenix SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual EirGenix SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It provides a comprehensive overview of the company's strategic position.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full EirGenix SWOT report you'll get. Purchase unlocks the entire in-depth version, detailing key internal and external factors impacting the business.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete EirGenix SWOT analysis. Once purchased, you’ll receive the full, editable version, ready for your strategic planning needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55538484216185,"sku":"eirgenix-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/eirgenix-swot-analysis.png?v=1753621539","url":"https:\/\/portersfiveforce.com\/products\/eirgenix-swot-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}